Takeda’s narcolepsy drug approved by the FDA, seen as a boon for new class of treatments
Orexin receptor agonists are being tested in a wide range of neurologic conditions
Adobe
By Elaine Chen
Aug. 5, 2026
Chen, a national biotech reporter, is the co-author of The Readout, a newsletter about the business, science, and politics of biotech.
Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70.
The Food and Drug Administration on Wednesday approved a novel type of treatment for narcolepsy made by Takeda, backing a drug class that scientists hope can transform the treatment of sleep disorders and potentially address a broad range of neurologic conditions.
The twice-a-day pill, which will be marketed as Orzeyful, is an orexin receptor agonist. It’s cleared to treat narcolepsy type 1, a taxing condition in which patients have a deficiency of the orexin neuron and experience bouts of sleepiness and muscle weakness during the day.
Advertisement
The drug is likely to be very appealing to patients. Current therapies, stimulants and sodium oxybates, carry risk of misuse, and patients still feel sleepy while taking them. In two Phase 3 trials, Orzeyful helped patients stay awake during the day for much longer than what’s been seen with current treatments. Throughout the studies, participants also reported less daytime sleepiness, less frequent muscle weakness, and greater attentiveness.
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Individual plans
Group plans
Monthly
$39
Totals $468 per year
Totals $468 per year
Starter
$30
for 3 months, then $399/year
Then $399/year
Annual
$399
Save 15%
Save 15%
11+ Users
Custom
Savings start at 25%!
Request A Quote Request A Quote
Savings start at 25%!
2-10 Users
$300
Annually per user
$300 Annually per user
To read the rest of this story subscribe to STAT+.
biotechnology, chronic diseases, drug development, Pharmaceuticals, STAT+, Takeda
Submit a correction request Reprints
National Biotech Reporter
Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70.
Newsletter
Your morning rundown of the science, politics, and money driving biotech today
Please enter a valid email address.Sign Up
Your data will be processed in accordance with our Privacy Policy and Terms of Service. You may opt out of receiving STAT communications at any time.
Once again, child dies in gene-editing trial in China, rekindling debate on transparency and safety
Erica Schwartz confirmed as CDC director, filling nearly yearlong vacancy
Senate inquiry suggests Trump administration softened kratom and tobacco policies in quid pro quo
Could poop pills be the next treatment for food allergies?
\
2025 Edition: Ranking Biotech’s Top Venture Capital Firms
\
\
AAIC Recap: What’s Next in Alzheimer’s\
\
Virtual Jul 16 
\
\
Office Hours with STAT’s Bob Herman\
\
Virtual Jul 22 
\
\
Office Hours with Isabella Cueto and Lev Facher\
\
Virtual Jul 29
Eli Lilly to allow more patients to apply for special access to unapproved obesity drug
Trump administration revises rebate pilot for 340B drug discount program, angering hospitals
A most-wanted fugitive appears to have been secretly working as a biotech executive
FDA expert panel recommends against approval of Capricor’s Duchenne drug
FDA expert committee votes in favor of Replimune’s melanoma treatment
Recommended
Biotech
BiotechAugust 5, 2026
FDA approves Moderna’s mRNA flu vaccine, the first to use the technology
Exclusive
ExclusiveAugust 5, 2026
STAT Plus: Once again, child dies in gene-editing trial in China, rekindling debate on transparency and safety
The Readout
The ReadoutAugust 5, 2026
STAT Plus: Moderna launches early trial of Ebola mRNA vaccine
Pharma
PharmaAugust 5, 2026
STAT Plus: Exemption of rare disease therapies in drug-pricing pilots would wipe out huge savings, analysis finds
Exclusive
ExclusiveAugust 4, 2026